Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging study of asfotase alfa in hypophosphatasia
2017-001831-38Phase 2
- Sponsor
- Alexion Pharmaceuticals
- Start
- May 2017
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of asfotase alfa in hypophosphatasia (HPP) (2 arms), sponsored by Alexion Pharmaceuticals. Primary endpoints: Reduction in plasma inorganic pyrophosphate (PPi) and Reduction in plasma pyridoxal-5' phosphate (PLP).
02
Drugs
asfotase alfa
03
Conditions
hypophosphatasia (HPP)
Beyond the preview
Go deeper on 2017-001831-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001831-38.